Vedantra Pharmaceuticals
Cambridge, US · Delaware corporation
Founders & leadership
Board
IK
Isaac KohlbergBoard director
SD
Steve DeitcherBoard director
SJ
Satish JindalBoard director
WK
William KosterBoard director
Reported raises · per SEC filings
Form D private placements$102M disclosed across 9 rounds · 2016–2022
▶$22MraisedNov 2022 · 7 investors · BiotechnologyRule 506(b)
▶$22MraisedNov 2022 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert RuffoloDirector
- Yekaterina ChudnovskyDirector
- Robert ConnellyExecutive Officer, Director
- Carol AsheDirector
- Annette MatthiesExecutive Officer
- Assaf SegalDirector
- Daniel GeffkenExecutive Officer, Director
- Julian AdamsDirector
- Christopher HaqqExecutive Officer
- Daphne KarydasDirector
- Offering amount
- $50M
- Amount sold
- $22M
- Finders' fees
- $989.8K
- Placement agents
- Finalis Securities LLC
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.5MraisedNov 2021 · 4 investors · BiotechnologyRule 506(b)
▶$14.5MraisedNov 2021 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daphne KarydasDirector
- Ofer GonenDirector
- Annette MatthiesExecutive Officer
- Julian AdamsDirector
- Robert RuffoloDirector
- Robert ConnellyExecutive Officer, Director
- Daniel GeffkenExecutive Officer, Director
- Carol AsheDirector
- Christopher HaqqExecutive Officer
- Offering amount
- $15M
- Amount sold
- $14.5M
- Finders' fees
- $341.1K
- Placement agents
- Finalis Securities LLC
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.1MraisedJul 2020 · 49 investors · BiotechnologyRule 506(b)
▶$6.1MraisedJul 2020 · 49 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher HaqqExecutive Officer
- Isaac KohlbergDirector
- Julian AdamsDirector
- Robert RuffoloDirector
- Daniel GeffkenExecutive Officer, Director
- Robert ConnellyExecutive Officer, Director
- Offering amount
- $30M
- Amount sold
- $6.1M
- Sales commissions
- $608.5K
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.4MraisedMar 2020 · 108 investors · BiotechnologyRule 506(b)
▶$8.4MraisedMar 2020 · 108 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert RuffoloDirector
- Isaac KohlbergDirector
- Daniel GeffkenExecutive Officer, Director
- Julian AdamsExecutive Officer, Director
- Robert ConnellyExecutive Officer, Director
- Offering amount
- $8.4M
- Amount sold
- $8.4M
- Sales commissions
- $841.2K
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7MraisedOct 2019 · 2 investors · BiotechnologyRule 506(b)
▶$7MraisedOct 2019 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Julian AdamsDirector, Executive Officer
- Robert RuffoloDirector
- Daniel GeffkenExecutive Officer, Director
- Robert ConnellyExecutive Officer, Director
- Isaac KohlbergDirector
- Frank HaluskaDirector
- Offering amount
- $7M
- Amount sold
- $7M
- Sales commissions
- $700K
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25.8MraisedSep 2018 · 137 investors · BiotechnologyRule 506(b)
▶$25.8MraisedSep 2018 · 137 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Isaac BlechDirector
- William KosterDirector
- Daniel GeffkenExecutive Officer, Director
- Isaac KohlbergDirector
- Frank HaluskaDirector
- Julian AdamsDirector
- Offering amount
- $36.2M
- Amount sold
- $25.8M
- Sales commissions
- $525K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.5MraisedAug 2018 · 115 investors · BiotechnologyRule 506(b)
▶$14.5MraisedAug 2018 · 115 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William KosterDirector
- Daniel GeffkenExecutive Officer, Director
- Frank HaluskaDirector
- Isaac KohlbergDirector
- Julian AdamsDirector
- Isaac BlechDirector
- Satish JindalDirector
- Offering amount
- $14.5M
- Amount sold
- $14.5M
- Sales commissions
- $1.4M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedJun 2018 · 27 investors · BiotechnologyRule 506(b)
▶$3MraisedJun 2018 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Isaac BlechDirector
- Daniel GeffkenExecutive Officer, Director
- Satish JindalDirector
- Julian AdamsDirector
- Frank HaluskaDirector
- Isaac KohlbergDirector
- William KosterDirector
- Offering amount
- $3M
- Amount sold
- $3M
- Sales commissions
- $299K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Vedantra Pharmaceuticals raised?
- Vedantra Pharmaceuticals has disclosed $102M raised across 9 rounds.
- Where is Vedantra Pharmaceuticals headquartered?
- Vedantra Pharmaceuticals is headquartered in Cambridge, US.